Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTOSTAR: Guselkumab in Pediatric Chronic Plaque Psoriasis
NCT03451851Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriasis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Investigator's Global Assessment Score of Cleared (0) or Minimal (1) at 16 weeks and Psoriasis Area and Severity Index 75 Response at 16 weeks. Started Jul 2018; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03451851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451851.